alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

30,580 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 5,551–5,575 of 17,283 studies scoring 30–49 out of 100 (page 223 of 692) · 30,580 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 16,054 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Trends, inequalities, and cross-location similarities in global dementia burden and attributable risk factors across 204 countries and territories: a systematic analysis for the Global Burden of Disease Study 2021

✓ Peer-reviewed alzhub usefulness score 43 out of 100. International Journal of Surgery 2025-06-20

In 2021, dementia accounted for 56.9 million global cases, 2.0 million deaths, and 36.3 million DALYs. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Global burden, quality of care, and cross-country inequalities in Alzheimer’s disease and other dementias from 1990 to 2021

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Journal of Global Health 2025-10-03

The global age-standardised DALY rates of ADRDs per 100 000 population slightly increased from 1331.59 (95% confidence interval (CI) = 881.57, 1781.61) in 1990 to 1347.24 (95% CI = 906.36, 1788.12) in 2021, with an AAPC of 0.04% (95% CI = 0.02, 0.05). 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Enhancing the validity of CAIDE dementia risk scores with resting heart rate and machine learning: An analysis from the National Alzheimer's Coordinating Center across all races/ethnicities

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Alzheimer s & Dementia 2025-08-01

Incorporating RHR into the CAIDE model significantly improved predictive accuracy across Black African, Asian, White, and Native Hawaiian populations (mean AUC range: 0.80-0.91). 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Trends and forecasts of the prevalence and mortality of Alzheimer’s disease and other dementias in China

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Frontiers in Public Health 2025-07-22

In 2021, the age-standardized prevalence of AD and other dementia in China was 1,194 per 100,000 (95% CI: 1018-1,383), and the mortality rate was 35 per 100,000 (95% CI: 9-93). 5 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Global trends in prevalence, disability adjusted life years, and risk factors for early onset dementia from 1990 to 2021

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Scientific Reports 2025-04-18

This study aims to analyze temporal trends in the prevalence and disability-adjusted life year (DALY) burden of early-onset dementia (EOD) globally from 1990 to 2021 and assess the attributable burdens of modifiable risk factors. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Knowledge and attitudes about dementia and dementia genetics in a cohort of geriatric clinic attendees in Nigeria

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Journal of Alzheimer s Disease 2025-04-22

BackgroundPopulation ageing in Africa will increase the burden of Alzheimer's disease and related dementias within the next few decades. 1 key finding →

Participants: 42 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Regional differences in the incidence of Alzheimer’s disease and related dementias in South Carolina

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Frontiers in Neurology 2025-09-05

Regional differences in the incidence of ADRD suggest possible disparities in healthcare access, socioeconomic conditions and geographical factors. 2 key findings →

Participants: 18,955 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Autism and Dementia: A Summative Report from the 2nd International Summit on Intellectual Disabilities and Dementia

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Journal of Autism and Developmental Disorders 2025-05-06

This article synthesizes findings, from the Autism/Dementia Work Group of the 2nd International Summit on Intellectual Disabilities and Dementia, on the nature of autism/autism spectrum disorder and later-age neuropathologies, particularly dementia. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Alzheimer’s Disease: Exploring Pathophysiological Hypotheses and the Role of Machine Learning in Drug Discovery

✓ Peer-reviewed alzhub usefulness score 43 out of 100. International Journal of Molecular Sciences 2025-01-24

Alzheimer’s disease (AD) is a major neurodegenerative dementia, with its complex pathophysiology challenging current treatments. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Artificial intelligence in neurodegenerative diseases research: a bibliometric analysis since 2000

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Frontiers in Neurology 2025-07-16

This bibliometric review examines the evolving landscape of artificial intelligence (AI) in neurodegenerative diseases research from 2000 to March 16, 2025, utilizing data from 1,402 publications (1,159 articles, 243 reviews) indexed in the Web of Science Core Collection. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Biomarker Investigation Using Multiple Brain Measures from MRI Through Explainable Artificial Intelligence in Alzheimer’s Disease Classification

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Bioengineering 2025-01-17

As the leading cause of dementia worldwide, Alzheimer’s Disease (AD) has prompted significant interest in developing Deep Learning (DL) approaches for its classification. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Comprehensive Machine Learning-Based Prediction Model for Delirium Risk in Older Patients with Dementia: Risk Factors Identification

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Clinical Interventions in Aging 2025-05-01

The final analysis included 636 older dementia patients, with a mean age of 78.2 ± 6.3 years, of whom 187 (29.4%) developed delirium during hospitalization. 5 key findings →

Participants: 636 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Research progress in predicting the conversion from mild cognitive impairment to Alzheimer’s disease via multimodal MRI and artificial intelligence

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Frontiers in Neurology 2025-06-02

Predicting the transition from mild cognitive impairment (MCI) to Alzheimer's disease (AD) has important clinical significance for dementia prevention and improving patient prognosis. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Electroencephalogram and Event-Related Potential in Mild Cognitive Impairment: Recent Developments in Signal Processing, Machine Learning, and Deep Learning

✓ Peer-reviewed alzhub usefulness score 43 out of 100. IEEE Journal of Selected Areas in Sensors 2025-01-01

Mild cognitive impairment (MCI) is an early stage of non-age-related cognitive decline with an increased risk of progressing to dementia. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Machine learning models for dementia screening to classify brain amyloid positivity on positron emission tomography using blood markers and demographic characteristics: a retrospective observational study

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Alzheimer s Research & Therapy 2025-01-21

Data from 262 records (260 unique participants) were analyzed. 5 key findings →

Participants: 15 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Application of machine learning in EEG-based dementia diagnosis: Classification and differential diagnosis

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Journal of Alzheimer s Disease 2025-07-28

BackgroundElectroencephalogram (EEG) is a promising, non-invasive method for identifying the presence of Alzheimer's disease (AD) by recognizing specific brain activity patterns associated with the disease. 3 key findings →

Participants: 431 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Identification of UBE2N as a biomarker of Alzheimer’s disease by combining WGCNA with machine learning algorithms

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Scientific Reports 2025-02-22

Alzheimer’s disease (AD) is the most common cause of dementia, emphasizing the critical need for the development of biomarkers that facilitate accurate and objective assessment of disease progression for early detection and intervention to delay its onset. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Aging, mitochondrial dysfunction, and cerebral microhemorrhages: a preclinical evaluation of SS-31 (elamipretide) and development of a high-throughput machine learning-driven imaging pipeline for cerebromicrovascular protection therapeutic screening

✓ Peer-reviewed alzhub usefulness score 43 out of 100. GeroScience 2025-04-02

Cerebral microhemorrhages (CMHs, also known as cerebral microbleeds) contribute to vascular cognitive impairment and dementia (VCID), with aging and hypertension being key risk factors. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The Application of Artificial Intelligence to Older Adults With Disabilities: A Scoping Review

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Journal of Applied Gerontology 2026-01-20

ObjectiveTo review the application of artificial intelligence (AI) in the care of older adults with disabilities, identifying intervention type, target populations, and effects. 5 key findings →

Participants: 15 Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Gait and movement analysis for discrimination between people with dementia and healthy control persons based on pose estimation and machine learning

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Journal of Alzheimer s Disease 2026-03-15

BackgroundDementia disorders are affecting millions of people globally, characterized by memory loss, communication difficulties, and motor function decline. 1 key finding →

Participants: 64 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

The global, regional, and national burden and attributable risk factors of Alzheimer's disease and other dementias, 1990-2021: A systematic analysis for the Global Burden of Disease Study

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Journal of Alzheimer s Disease 2025-07-21

BackgroundDementia is a syndrome characterized by a decline in cognitive function, with Alzheimer's disease (AD) being the most common type. 3 key findings →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 30,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,580 records, built mostly from automated pulls of Europe PMC (64.7% of the library) and OpenAlex (16.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,037 records (3.4% of the library) are not peer-reviewed — 964 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events